A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathy, Inflammatory Demyelinating, Chronic

Interventions

DRUG: Riliprubart
DRUG: Placebo
DRUG: Riliprubart
DRUG: Placebo

Sponsor

Sanofi